{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "This study aimed to evaluate whether PLX-PAD would increase amputation-free survival in people with CLTI who were not candidates for revascularization."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomized, parallel-group, placebo-controlled, multinational, blinded, trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "People with CLTI and minor tissue loss (Rutherford 5) who were unsuitable for revascularization"
      },
      "Intervention": {
        "score": 2,
        "evidence": "PLX-PAD was compared with placebo (2 : 1 randomization), with 30 intramuscular injections (0.5\u2005ml each) into the index leg on days 0 and 60."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate whether PLX-PAD would increase amputation-free survival in people with CLTI who were not candidates for revascularization."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Planned follow-up was 12\u201336 months, and included vital status, amputations, lesion size, pain and quality-of-life assessments, haemodynamic parameters, and adverse events."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "randomized, parallel-group, placebo-controlled, multinational, blinded, trial"
      },
      "Blinding": {
        "score": 2,
        "evidence": "blinded, trial"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 213 patients enrolled, 143 were randomized to PLX-PAD and 70 to placebo."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 213 patients enrolled, 143 were randomized to PLX-PAD and 70 to placebo."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The probability of major amputation or death was similar for placebo and PLX-PAD (33 and 28.6% respectively; HR 0.93, 95% c.i. 0.53 to 1.63; P = 0.788)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Most patients (76.6%) reported at least one adverse event, which were mostly expected events in CLTI, such as skin ulcer or gangrene."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT03006770 ( http://www.clinicaltrials.gov ); 2015-005532-18 (EudraCT Clinical Trials register - Search for 2015-005532-18)."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 19,
    "max_score": 25
  },
  "model": "gpt-4o"
}